Formulation, optimization, and characterization of rifampicin-loaded solid lipid nanoparticles for the treatment of tuberculosis

References

• Global Tuberculosis Report [Internet]. Geneva: World Health Organization; [updated 2016; cited 2017 Oct 25]. Available from: http://www.who.int/tb/publications/global_report/en/
   Google Scholar
• Sosnik A, Carcaboso AM, Glisoni RJ, et al. New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv Drug Deliv Rev. 2010;62:547–559.
   PubMed Web of Science ®Google Scholar
• Goyal AK, Garg T, Rath G, et al. Chemotherapeutic evaluation of guar gum coated chitosan nanoparticle against experimental tuberculosis. J Biomed Nanotechnol. 2016;12:450–463.
   PubMed Web of Science ®Google Scholar
• Shishoo CJ, Shah SA, Rathod IS, et al. Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation. Int J Pharm. 2001;228:53–67.
   PubMed Web of Science ®Google Scholar
• Singh S, Mariappan TT, Shankar R, et al. A critical review of the probable reasons for the poor variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem. Int J Pharm. 2001;228:5–17.
   PubMedGoogle Scholar
• IUATLD/WHO. The promise and reality of fixed-dose combinations with rifampicin. A joint statement of International Union against Tuberculosis and Lung Diseases and the Tuberculosis Programme of the World Health Organisation. 1994.
   Google Scholar
• Singh H, Bhandari R, Kaur IP. Encapsulation of Rifampicin in a solid lipid nanoparticulate system to limit its degradation and interaction with Isoniazid at acidic pH. Int J Pharm. 2013;446:106–111.
   PubMed Web of Science ®Google Scholar
• Shete H, Patravale V. Long chain lipid based tamoxifen NLC. Part I: preformulation studies, formulation development and physicochemical characterization. Int J Pharm. 2013;454:573–583.
   PubMed Web of Science ®Google Scholar
• Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6:231–248.
   PubMed Web of Science ®Google Scholar
• Porter CJ, Pouton CW, Cuine JF, et al. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev. 2008;60:673–691.
   PubMed Web of Science ®Google Scholar
• Pouton CW, Porter CJ. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv Drug Deliv Rev. 2008;60:625–637.
   PubMed Web of Science ®Google Scholar
• Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev. 2008;60:702–716.
   PubMed Web of Science ®Google Scholar
• Zilly W, Breimer DD, Richter E. Pharmacokinetic Interactions with Rifampicin. Clinical Pharmacokinetics. 1977;2:61–70.
   PubMed Web of Science ®Google Scholar
• Acocella G. Pharmacokinetics and metabolism of rifampin in humans. Rev Infect Dis. 1983;5 (Suppl 3):S428–S432.
   PubMedGoogle Scholar
• Caliph SM, Charman WN, Porter CJH. Effect of short‐, medium‐, and long‐chain fatty acid‐based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph‐cannulated and non‐cannulated rats. J Pharm Sci. 2000;89:1073–1084.
   PubMed Web of Science ®Google Scholar
• Noguchi T, Charman WNA, Stella VJ. The effect of drug lipophilicity and lipid vehicles on the lymphatic absorption of various testosterone esters. Int J Pharm. 1985;24:173–184.
   Web of Science ®Google Scholar
• O’Driscoll CM. Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci. 2002;15:405–415.
   PubMed Web of Science ®Google Scholar
• Chaudhary S, Garg T, Murthy RS, et al. Recent approaches of lipid-based delivery system for lymphatic targeting via oral route. J Drug Target. 2014;22:871–882.
   PubMed Web of Science ®Google Scholar
• Singh I, Swami R, Khan W, et al. Lymphatic system: a prospective area for advanced targeting of particulate drug carriers. Expert Opin Drug Deliv. 2014;11:211–229.
   PubMed Web of Science ®Google Scholar
• Shete H, Chatterjee S, De A, et al. Long chain lipid based tamoxifen NLC. Part II: pharmacokinetic, biodistribution and in vitro anticancer efficacy studies. Int J Pharm. 2013;454:584–592.
   PubMed Web of Science ®Google Scholar
• Ali Khan A, Mudassir J, Mohtar N, et al. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomed. 2013;8:2733–2744.
   PubMed Web of Science ®Google Scholar
• Cai S, Yang Q, Bagby TR, et al. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv Drug Deliv Rev. 2011;63:901–908.
   PubMed Web of Science ®Google Scholar
• Yanez JA, Wang SW, Knemeyer IW, et al. Intestinal lymphatic transport for drug delivery. Adv Drug Deliv Rev. 2011;63:923–942.
   PubMed Web of Science ®Google Scholar
• Paliwal R, Rai S, Vaidya B, et al. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomed Nanotechnol Biol Med. 2009;5:184–191.
   PubMed Web of Science ®Google Scholar
• Pouplin T, Phuong PN, Toi PV, et al. Isoniazid, pyrazinamide and rifampicin content variation in split fixed-dose combination tablets. PLoS One. 2014;9:e102047.
   PubMed Web of Science ®Google Scholar
• IBorman P, Elder D. Q2(R1) validation of analytical procedures. ICH quality guidelines [Internet]. John Wiley & Sons, Inc. p. 127–166; [cited 2017 Sep 29] Available from: http://dx.doi.org/10.1002/9781118971147.
   Google Scholar
• Patel K, Padhye S, Nagarsenker M. Duloxetine HCl lipid nanoparticles: preparation, characterization, and dosage form design. AAPS PharmSciTech. 2012;13:125–133.
   PubMed Web of Science ®Google Scholar
• Singh H, Jindal S, Singh M, et al. Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety. Int J Pharm. 2015;485:138–151.
   PubMed Web of Science ®Google Scholar
• Dwivedi P, Khatik R, Khandelwal K, et al. Pharmacokinetics study of arteether loaded solid lipid nanoparticles: an improved oral bioavailability in rats. Int J Pharm 2014;466:321–327.
   PubMed Web of Science ®Google Scholar
• Varshosaz J, Eskandari S, Tabbakhian M. Freeze-drying of nanostructure lipid carriers by different carbohydrate polymers used as cryoprotectants. Carbohydrate Polymers. 2012;88:1157–1163.
   Web of Science ®Google Scholar
• Gaspar DP, Faria V, Goncalves LM, et al. Rifabutin-loaded solid lipid nanoparticles for inhaled antitubercular therapy: physicochemical and in vitro studies. Int J Pharm. 2016;497:199–209.
   PubMed Web of Science ®Google Scholar
• Pinheiro M, Ribeiro R, Vieira A, et al. Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis. Drug Des Devel Ther. 2016;10:2467–2475.
   PubMed Web of Science ®Google Scholar
• Prabhakar K, Afzal SM, Kumar PU, et al. Brain delivery of transferrin coupled indinavir submicron lipid emulsions-pharmacokinetics and tissue distribution. Colloids Surf B Biointerf. 2011;86:305–313.
   PubMed Web of Science ®Google Scholar
• LiYang YG, Li H, Zhang Y, et al. Enhancement the oral bioavailability of praziquantel by incorporation into solid lipid nanoparticles. Pharmazie. 2009;64:86–89.
   PubMed Web of Science ®Google Scholar
• Subedi RK, Kang KW, Choi HK. Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. Eur J Pharm Sci. 2009;37:508–513.
   PubMed Web of Science ®Google Scholar
• Ravi PR, Aditya N, Kathuria H, et al. Lipid nanoparticles for oral delivery of raloxifene: optimization, stability, in vivo evaluation and uptake mechanism. Eur J Pharm Biopharm. 2014;87:114–124.
   PubMed Web of Science ®Google Scholar
• Luo Y, Chen D, Ren L, et al. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Controlled Release. 2006;114:53–59.
   PubMed Web of Science ®Google Scholar
• Garanti T, Stasik A, Burrow AJ, et al. Anti-glioma activity and the mechanism of cellular uptake of asiatic acid-loaded solid lipid nanoparticles. Int J Pharm. 2016;500:305–315.
   PubMed Web of Science ®Google Scholar
• Kumar PV, Asthana A, Dutta T, et al. Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers. J Drug Target. 2006;14:546–556.
   PubMed Web of Science ®Google Scholar
• Ashay Jain AA, Majumder S, Lariya N, et al. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Release. 2010;148:359–367.
   PubMed Web of Science ®Google Scholar
• Vandal OH, Nathan CF, Ehrt S. Acid resistance in Mycobacterium tuberculosis. J Bacteriol. 2009;191:4714–4721.
   PubMed Web of Science ®Google Scholar
• Gao Y, Sarfraz MK, Clas S-D, et al. Hyaluronic acid-tocopherol succinate-based self-assembling micelles for targeted delivery of rifampicin to alveolar macrophages. J Biomed Nanotechnol. 2015;11:1312–1329.
   PubMed Web of Science ®Google Scholar
• Zhang X, Chen G, Zhang T, et al. Effects of PEGylated lipid nanoparticles on the oral absorption of one BCS II drug: a mechanistic investigation. Int J Nanomedicine. 2014;9:5503–5514.
   PubMed Web of Science ®Google Scholar
• Benito-Gallo P, Franceschetto A, Wong JC, et al. Chain length affects pancreatic lipase activity and the extent and pH-time profile of triglyceride lipolysis. Eur J Pharm Biopharm. 2015;93:353–362.
   PubMed Web of Science ®Google Scholar
• Thomas N, Holm R, Rades T, et al. Characterising lipid lipolysis and its implication in lipid-based formulation development. Aaps J. 2012;14:860–871.
   PubMed Web of Science ®Google Scholar
• Estella-Hermoso de Mendoza A, Campanero MA, Mollinedo F, et al. Lipid nanomedicines for anticancer drug therapy. J Biomed Nanotechnol. 2009;5:323–343.
   PubMed Web of Science ®Google Scholar
• Kalaria DR, Sharma G, Beniwal V, et al. Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res. 2009;26:492–501.
   PubMed Web of Science ®Google Scholar
• Abdelwahed W, Degobert G, Fessi H. Investigation of nanocapsules stabilization by amorphous excipients during freeze-drying and storage. Eur J Pharm Biopharm. 2006;63:87–94.
   PubMed Web of Science ®Google Scholar
• Pandita D, Ahuja A, Lather V, et al. Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. AAPS PharmSciTech. 2011;12:712–722.
   PubMed Web of Science ®Google Scholar
• European Chemicals Agency (ECHA) - Octadecylamine Europe: ECHA EUROPA; 2017 [cited 2017 8 Jan]. Available from: https://echa.europa.eu/brief-profile/-/briefprofile/100.004.270.
   Google Scholar
• Harde H, Das M, Jain S. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert Opin Drug Deliv. 2011;8:1407–1424.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Arrivo SM, Thurau G, et al. Spectroscopic approach for on-line monitoring of particle size during the processing of pharmaceutical nanoparticles. Anal Chem. 2003;75:1777–1785.
   PubMed Web of Science ®Google Scholar
• Sandip S, Chavan SGI, Vavia PR. Preparation and characterization of solid lipid nanoparticle-based nasal spray of budesonide. Drug Deliv and Transl Res. 2012.
   Web of Science ®Google Scholar
• Das S, Ng WK, Tan RB. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci. 2012;47:139–151.
   PubMed Web of Science ®Google Scholar
• Torcello-Gómez A, Maldonado-Valderrama J, Jódar-Reyes AB, et al. Interactions between pluronics (F127 and F68) and bile salts (NaTDC) in the aqueous phase and the interface of oil-in-water emulsions. Langmuir 2013;29:2520–2529.
   PubMed Web of Science ®Google Scholar
• Müller RH, Maassen S, Weyhers H, et al. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Target. 1996;4:161–170.,
   PubMed Web of Science ®Google Scholar
• Shah M, Agrawal YK, Garala K, et al. Solid lipid nanoparticles of a water soluble drug, ciprofloxacin hydrochloride. Indian J Pharm Sci. 2012;74:434–442.
   PubMed Web of Science ®Google Scholar
• Schwarz C, Mehnert W, Lucks JS, et al. Solid lipid nanoparticles (SLN) for controlled drug delivery-I. Production, characterization and sterilization. J Control Release. 1994;30:83–96.
   Web of Science ®Google Scholar
• Bhalekar M, Upadhaya P, Madgulkar A. Formulation and characterization of solid lipid nanoparticles for an anti-retroviral drug darunavir. Appl Nanosci. 2017;7:47–57.
   Web of Science ®Google Scholar
• Vivek K, Reddy H, Murthy RSR. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles. AAPS PharmSciTech. 2007;8:16.
   PubMed Web of Science ®Google Scholar
• Muchow M, Maincent P, Muller RH. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm. 2008;34:1394–1405.
   PubMed Web of Science ®Google Scholar
• Pople P, Singh KK, Rowe RC, et al. Handbook of pharmaceutical excipients. 7th ed. Vol. 18. UK: Informa UK Limited. Pharmaceutical development and technology; 2013.
   Google Scholar
• Leroux J-C, Allémann E, Doelker E, et al. New approach for the preparation of nanoparticles by an emulsification-diffusion method. Eur J Pharm Biopharm. 1995;41:14–18.
   Web of Science ®Google Scholar
• Das S, Ng WK, Kanaujia P, et al. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables. Colloids Surf B Biointerf. 2011;88:483–489.
   PubMed Web of Science ®Google Scholar
• Sinhmar G, Shah N, Chokshi N, et al. Process, optimization, and characterization of budesonide-loaded nanostructured lipid carriers for the treatment of inflammatory bowel disease. Drug Dev. Ind. Pharm. 2018; 44(7):1078–1089.
   PubMed Web of Science ®Google Scholar
• Bunjes H, Koch MHJ, Westesen K. Influence of emulsifiers on the crystallization of solid lipid nanoparticles. J Pharm Sci. 2003;92:1509–1520.
   PubMed Web of Science ®Google Scholar
• Barzegar-Jalali M, Adibkia K, Valizadeh H, et al. Kinetic analysis of drug release from nanoparticles. J Pharm Pharm Sci. 2008;11:167–177.
   PubMed Web of Science ®Google Scholar
• Patel MM. Formulation and development of di-dependent microparticulate system for colon-specific drug delivery. Drug Deliv Transl Res. 2017;7:312–324.
   PubMed Web of Science ®Google Scholar
• Xu J, Bovet LL, Zhao K. Taste masking microspheres for orally disintegrating tablets. Int J Pharm. 2008;359:63–69.
   PubMed Web of Science ®Google Scholar
• Jose S, Prema MT, Chacko AJ, et al. Colon specific chitosan microspheres for chronotherapy of chronic stable angina. Colloids Surf B Biointerf. 2011;83:277–283.
   PubMed Web of Science ®Google Scholar
• Ricardo Alves TVdSR, P, Mercuri L. C C d, Silva J. d R, Matos S, Storpírtis L. Thermal behavior and decomposition kinetics of rifampicin polymorphs under isothermal and non-isothermal conditions. Braz J Pharm Sci. 2010;46:343.
   Web of Science ®Google Scholar
• Gallo GG, Radaelli P. Rifampin. In: Florey K, editor. Analytical profiles of drug substances. Vol. 5. New York (NY): Academic Press; 1976. p. 467–513.
   Google Scholar
• Ibiapino AL, Seiceira RC, Pitaluga A, et al. Structural characterization of form I of anhydrous rifampicin. CrystEngComm. 2014;16:8555.
   Web of Science ®Google Scholar